Call for Abstract

14th Global Biomarkers Summit, will be organized around the theme “Advancements in Biomarkers from Translational Research to Commercialization”

Biomarkers Summit 2018 is comprised of keynote and speakers sessions on latest cutting edge research designed to offer comprehensive global discussions that address current issues in Biomarkers Summit 2018

Submit your abstract to any of the mentioned tracks.

Register now for the conference by choosing an appropriate package suitable to you.

  • Track 1-1Nucleic acid-based Biomarkers
  • Track 1-2Protein Biomarkers
  • Track 1-3Small molecule Biomarkers
  • Track 1-4Lipid Biomarkers
  • Track 1-5MicroRNA Biomarkers
  • Track 2-1Predictive Biomarkers to immunotherapies
  • Track 2-2Mutation analysis using Biomarkers to guide therapies
  • Track 2-3Biomarkers in Immune monitoring
  • Track 2-4Biomarkers for precision immune-oncology
  • Track 2-5Tumor Microenvironment profiling
  • Track 2-6Role of Biomarkers in Cancer Vaccines development
  • Track 2-7Evaluation of Biomarkers in clinical trials
  • Track 2-8Biomarkers for combinational immunotherapies
  • Track 2-9Tumor Neoantigens as Biomarker and target identification
  • Track 2-10Liquid Biopsy for Immuno-Oncology
  • Track 2-11Prognostic Biomarkers
  • Track 2-12Biomarkers in Companion Diagnostics
  • Track 2-13Cell proliferation Biomarkers
  • Track 3-1Translating Biomarkers in Precision Medicine
  • Track 3-2Translating Biomarkers into Complementary & Companion Diagnostics
  • Track 3-3Genomics & proteomics evaluations: Role of Biomarkers & Case studies
  • Track 3-4Biomarkers for patient stratification in pre-clinical trials
  • Track 3-5Drug response test using Biomarkers
  • Track 3-6Biomarkers to guide clinical decision making & molecular profiling
  • Track 4-1Novel Biomarkers discovery
  • Track 4-2Clinical and analytical biomarker validation
  • Track 4-3Role of Biomarkers in clinical decision making
  • Track 4-4Application of Biomarkers in Drug discovery and development
  • Track 4-5Circulating Tumor DNA cells as Biomarkers: Case studies for various cancers
  • Track 4-6Non-invasive Biomarker for dug toxicity studies
  • Track 4-7Next-Generation Sequencing (NGS) assays for Translational and Clinical Research in Oncology
  • Track 4-8Biomarkers in Clinical trials: Design, strategies & application case studies
  • Track 5-1Biomarkers in Autoimmune disease
  • Track 5-2Biomarkers in Neuroscience
  • Track 5-3Biomarkers in Oncology
  • Track 5-4Biomarkers in Cardiovascular disease
  • Track 5-5Biomarkers in COPD, & Respiratory diseases
  • Track 5-6Biomarkers in Infectious Diseases
  • Track 5-7Biomarkers in Rheumatology
  • Track 5-8Biomarkers in Rare Diseases
  • Track 6-1Biomarkers for early identification of Neurological disorders
  • Track 6-2Biomarkers for monitoring of treatment efficiency & progression
  • Track 6-3High performance plasma amyloid-β biomarkers in Alzheimer’s disease
  • Track 7-1Biomarkers for Early Progressive Inflammatory & Immunological Diseases
  • Track 7-2Biomarkers as surrogate endpoints for Clinical Trials
  • Track 8-1Biomarkers for Heart Failure & Acute Coronary Syndrome
  • Track 8-2Biomarkers for Metabolic Syndrome & Cardiovascular Risk
  • Track 9-1Policy environment for Biomarker tests for Molecularly Targeted Therapies
  • Track 9-2Challenges and Issues in Biomarkers development
  • Track 9-3Policy issues in development and adoption of Biomarkers for Molecularly Targeted Cancer Therapies
  • Track 9-4Policy issues in the development of Personalized Medicine
  • Track 9-5coverage and reimbursement issues in Cancer biomarkers
  • Track 9-6Biomarkers & Drug labeling
  • Track 9-7Identification of molecular Biomarkers of clinical utility
  • Track 9-8Ethical, legal and social implications (ELSI) of Biomarkers
  • Track 9-9Difficulties in the development of an evidence base for evaluation of Biomarkers
  • Track 15-1NGS for the discovery of Biomarkers
  • Track 15-2MicroRNA sequencing for the prediction of diseases
  • Track 15-3SNP as Biomarkers
  • Track 15-4Cytogenetic & Oxidative stress Biomarkers
  • Track 15-5Genetic-based Biomarkers and NGS in personalized care of Cancer
  • Track 16-1Biosensors & wearables as Biomarker: Clinical development, Applications & Case studies
  • Track 16-2Digital end points in clinical trials
  • Track 16-3Mobile Health (m-health) in clinical trials
  • Track 16-4Digital Biomarkers in drug development
  • Track 16-5Regulatory aspects for medical app development: Commercialization and Clinical Trial Use
  • Track 16-6Machine learning & Internet of Things (IoT) application in Digital Biomarkers